Christina Ruhlmann

10PUBLICATIONS
33CO-AUTHORS
Predictive and prognostic markersMechanobiologyImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 10, 2026
The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy.

Anne-Line Mayland Madsen, Oke Gerke, Christina H Ruhlmann

|Oct 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Yago Garitaonaindia, Shawez Khan, Rasmus Friis

|Feb 26, 2025
Patient and Caregiver Education to Support Self-Efficacy and Self-Management During Immunotherapy-An Integrative Review.

Camilla S Rothausen, Karin B Dieperink, Christina H Ruhlmann

|Jul 27, 2024
Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases-A Danish Real-World Cohort.

Karoline Dreyer Kattenhøj, Christine Louise Møberg, Louise Mahncke Guldbrandt

|Apr 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.

Stine K Christensen, Mette L Winther, Ida J Laursen

|Dec 19, 2023
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.

Ian Olver, Rebecca Clark-Snow, Christina H Ruhlmann

Pageof 2

Frequent Collaborators

4 joint publications

Eva Ellebaek

3 joint publications

Inge Marie Svane

3 joint publications

Marco Donia

3 joint publications

Henrik Schmidt